These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 21839895)
21. [Current problems of outpatient psychiatric-psychotherapeutic care- the role of PIA]. Spengler A Psychiatr Prax; 2008 Oct; 35(7):361-4. PubMed ID: 18937193 [No Abstract] [Full Text] [Related]
22. [The role of economics in fair rationing]. Prenzler A Chirurg; 2012 Oct; 83(10):908-13. PubMed ID: 22915227 [TBL] [Abstract][Full Text] [Related]
23. Inequalities and healthcare reform in Chile: equity of what? Burrows J J Med Ethics; 2008 Sep; 34(9):e13. PubMed ID: 18757613 [TBL] [Abstract][Full Text] [Related]
24. Pricing-out effect from possible user-fee policies under Taiwan's National Health Insurance. Chen WY; Liang YW; Lin YH Expert Rev Pharmacoecon Outcomes Res; 2010 Aug; 10(4):453-64. PubMed ID: 20715921 [TBL] [Abstract][Full Text] [Related]
25. [Economic and ethical aspects of the development of treatment guidelines]. Lauterbach KW Z Arztl Fortbild Qualitatssich; 1997 Jun; 91(3):277-82. PubMed ID: 9312433 [TBL] [Abstract][Full Text] [Related]
26. [Does cost control in health care impose health care rationing?]. Meine J Swiss Surg; 1996; 2(4):141-2. PubMed ID: 9312388 [No Abstract] [Full Text] [Related]
27. [Health systems reform: What can western Europe contribute to Latin America?]. Infante A; Gozzer E Educ Med Salud; 1995; 29(3-4):286-303. PubMed ID: 8850123 [No Abstract] [Full Text] [Related]
29. [Pharmacoeconomic studies - usability for reimbursement decisions]. Dietrich ES; Nakashima T; Ahrens S Dtsch Med Wochenschr; 2010 Feb; 135(8):333-8. PubMed ID: 20165996 [TBL] [Abstract][Full Text] [Related]
30. Methods for determining cost-benefit ratios for pharmaceuticals in Germany. von der Schulenburg J; Vauth C; Mittendorf T; Greiner W Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539 [TBL] [Abstract][Full Text] [Related]
31. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria]. Führlinger S Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765 [TBL] [Abstract][Full Text] [Related]
32. A limitation to equal access in clinical trials: the Medicare review process. King SB; Kandzari DE JACC Cardiovasc Interv; 2013 Jun; 6(6):640-1. PubMed ID: 23787242 [No Abstract] [Full Text] [Related]
34. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement]. Hoomans T; van der Roer N; Severens JL; Delwel GO Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045 [TBL] [Abstract][Full Text] [Related]
35. An American-Canadian neurologist returns to Canada. Purves SJ; Purves GB Can J Neurol Sci; 2005 May; 32(2):264-5; author reply 266. PubMed ID: 16018169 [No Abstract] [Full Text] [Related]
36. Oral oncolytics: Part 2--legislation targeting cost & access, and other initiatives to reduce costs. Mancini R; McBride A; Kruczynski M Oncology (Williston Park); 2013 Sep; 27(9):865-6, 871. PubMed ID: 24282981 [No Abstract] [Full Text] [Related]
37. High or low risk coronary patients - who gets the highest priority? Ekroth R; Ståhle E Scand Cardiovasc J; 2010 Aug; 44(4):195-6. PubMed ID: 20636226 [TBL] [Abstract][Full Text] [Related]
38. Development and validation of a microsimulation economic model to evaluate the disease burden associated with smoking and the cost-effectiveness of tobacco control interventions in Latin America. Pichon-Riviere A; Augustovski F; Bardach A; Colantonio L; Value Health; 2011; 14(5 Suppl 1):S51-9. PubMed ID: 21839900 [TBL] [Abstract][Full Text] [Related]